

-continued

---

```

<221> NAME/KEY: modified_base
<222> LOCATION: (38)..(38)
<223> OTHER INFORMATION: mlg
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (39)..(39)
<223> OTHER INFORMATION: p
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (57)..(57)
<223> OTHER INFORMATION: m5c
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (64)..(64)
<223> OTHER INFORMATION: p
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (67)..(67)
<223> OTHER INFORMATION: mla

<400> SEQUENCE: 68

gguucucugg ccgagugguc uaaggcgcau gguuaagguc caugucucu cggaggcgcg      60
agtucgaacc ucgcgggaau cacca                                           85

```

---

What is claimed is:

1. A method of treating a human having onychomycosis of a toenail caused by *Trichophyton rubrum* or *Trichophyton mentagrophytes*, the method comprising:

topically administering to the toenail a pharmaceutical composition comprising an amount of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole or a pharmaceutically acceptable salt thereof, effective to inhibit an aminoacyl tRNA synthetase in the *Trichophyton rubrum* or *Trichophyton mentagrophytes*.

2. The method of claim 1, wherein the pharmaceutical composition is in the form of a solution comprising 5% w/w of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein the pharmaceutical composition further comprises ethanol and propylene glycol.

4. The method of claim 1, wherein the aminoacyl tRNA synthetase is leucyl tRNA synthetase.

5. The method of claim 4, wherein the pharmaceutical composition is in the form of a solution comprising 5% w/w

of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole or a pharmaceutically acceptable salt thereof.

6. The method of claim 5, wherein the pharmaceutical composition further comprises ethanol and propylene glycol.

7. The method of claim 1, wherein the administering of the pharmaceutical composition occurs once a day.

8. The method of claim 6, wherein the administering of the pharmaceutical composition occurs once a day.

9. The method of claim 1, wherein the method inhibits an aminoacyl tRNA synthetase in *Trichophyton rubrum*.

10. The method of claim 1, wherein the method inhibits an aminoacyl tRNA synthetase in *Trichophyton mentagrophytes*.

11. The method of claim 6, wherein the method inhibits leucyl tRNA synthetase in *Trichophyton rubrum*.

12. The method of claim 6, wherein the method inhibits leucyl tRNA synthetase in *Trichophyton mentagrophytes*.

\* \* \* \* \*